9
Participants
Start Date
January 31, 2005
Primary Completion Date
June 30, 2006
Study Completion Date
June 30, 2006
DermaVir
DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
HAART
Three or more antiretroviral drugs that can fully suppress HIV RNA
Saint Laszlo Hospital, Budapest
Lead Sponsor
Genetic Immunity
INDUSTRY